Accelerated approval is supported by 34-week interim data from the phase 3 I CAN trial showing a statistically significant 43% placebo-adjusted reduction in proteinuria.
The new 150mg oral pellet formulation provides a capsule-free prophylactic option for adults and adolescents with hereditary ...
Enzyme-inducing ASDs increase risk for incident osteoporosis or osteopenia, but few patients receive vitamin D supplementation.
The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.
HealthDay News — Benzodiazepine use in pregnancy is not associated with an increased risk for major congenital malformations, according to a study published online October 13 in the Annals of Internal ...
A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
The FDA has approved the first generic equivalent of Climara Pro, offering a once-weekly transdermal option for managing moderate to severe vasomotor symptoms and preventing postmenopausal ...
The investigational vaccine targets pathological amyloid-beta to lower brain amyloid in patients with preclinical Alzheimer ...
A new liquid formulation of cevimeline HCl offers a bioequivalent alternative for adult patients experiencing dry mouth ...
Patients with baseline viral suppression maintained viral suppression, while those without achieved viral suppression by 13 ...
Dostarlimab-gxly demonstrated high rates of sustained clinical complete response that allowed eligible patients to avoid chemotherapy, radiation, and surgery.
The application for the next-generation mitomycin formulation is supported by 3-month complete response data from the phase 3 UTOPIA trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results